Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 03, 2024 16:30 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 26, 2024 16:30 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in the Piper Sandler
36th Annual Healthcare Conference
Aclaris Therapeutics Announces $80 Million Private Placement
November 18, 2024 08:10 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces $80 Million Private Placement
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
November 18, 2024 08:10 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 06, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
September 17, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
September 10, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 07, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
July 16, 2024 16:01 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 06, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference